

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 1

**Complete if Known**

Application Number	New Application
Filing Date	herewith
First Named Inventor	Dewdney, Nolan James <i>et al.</i>
Art Unit	unassigned
Examiner Name	unassigned
Attorney Docket Number	R0164B-REG

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>2</sup> (if known)			
CMS	A1	US-2002/0061879 A1	05-23-2002	David S. Garvey, et al.	
	A2	US-3,594,480	07-20-1971	Timothy H. Cronin, et al.	
	A3	US-4,672,116	06-09-1987	Victor T. Bandurco, et al.	
	A4	US-5,084,463	01-28-1992	John A. Butera, et al.	
↓	A5	US-6,313,294 B1	11-06-2001	Wen-Chih Chou, et al.	

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)				
CMS	B1	WO 92/01675 A1 (PCT)	02-06-1992	Rhone-Poulenc Rorer S.A. (FR)		
	B2	WO 98/38984 A2 (PCT)	09-11-1998	Sugen, Inc. (U.S.)		
	B3	WO 01/32632 A2 (PCT)	05-10-2001	Eli Lilly and Company (U.S.)		
	B4	WO 01/38315 A1 (PCT)	05-31-2001	Warner-Lambert Company (U.S.)		
	B5	WO 01/64646 A2 (PCT)	09-07-2001	Tularik Inc (U.S.) & Sumitomo Pharma- ceuticals Co., Ltd. (JP)		
	B6	WO 02/085908 A1 (PCT)	10-31-2002	Purdue Research Foundation (U.S.) and Endocyte, Inc. (U.S.)		
	B7	WO 02/50045 A1 (PCT)	06-27-2002	Biota Scientific Management Pty (AU)		
	B8	WO 02/08224 A1 (PCT)	01-31-2002	SmithKline Beecham PLC (GB)		
↓	B9	EP 1 110 552 A1	06-27-2001	Aventis Pharma S.A. (FR)		

**OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS - None**Examiner  
Signature*Cecilia J. Smith*Date  
Considered

8/28/06

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 801.04. Doc. #124158